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Abstract
Fatty acid oxidation inhibition is one approach to reducing blood glucose levels in type II
diabetes. Skeletal muscle specific Carnitine Palmitoyltransferase 1b knockout mice (Cpt1b m-/-)
cannot transport long-chain fatty acids into the mitochondria to be oxidized in order to produce
energy. Cpt1bm-/- mice have debilitated fat oxidation, less fat mass and improved glucose
utilization compared to control C57BL/6 mice fed a 25% fat diet.
We hypothesized that CPT1b inhibition could reduce fat mass and lower blood glucose
levels in a genetic mouse model of obesity and diabetes. To test this, we bred Cpt1b m-/- mice to
AY mice. AY mice, also referred to as lethal yellow mice, are mutated at the mouse agouti locus
causing a yellow coat. AY mice are prone to obesity, diabetes, tumors and cancers. The goal of
this study was to determine the effect of extended inhibition of fatty acid transport into skeletal
muscle mitochondria in AY: Cpt1bm-/- mice.
Compared to AY mice, AY: Cpt1bm-/- mice were more insulin sensitive and glucose
tolerant. AY: Cpt1bm-/- mice showed improved performance on glucose and insulin tolerance tests
despite minimal differences in fat mass between groups. However, liver weights of A Y: Cpt1bm-/mice were significantly less than liver weights of A Y mice.

vii

Introduction
1.1. Modern Treatment Plans for Obesity and Type 2 Diabetes
Current treatment plans for obesity and type 2 diabetes include lifestyle-intervention
programs or administration of metformin. Both treatments have been shown to reduce the
incidence of diabetes in high risk individuals (Knowler, 2002). Thiazolidinediones (TZDs) drugs
serve as insulin sensitizers through decreasing the production and increasing the disposal of
glucose. TZD has been shown to activate AMPK and increase mitochondrial biogenesis in
adipose tissue (Wilson-Fritch et al., 2004). Mitochondrial inhibition in skeletal muscle also
improves insulin sensitivity (Pagel-Langenickel, Bao, Pang, & Sack, 2010). Investigation of
diabetic and obesogenic mouse models aids in the development of new treatment plans for the
prevention and amelioration of obesity and type 2 diabetes.
1.2. History of AY Mice
Lethal yellow (AY) mutated mice are a genetically obese and diabetic mouse model
commonly used for the study of obesity and insulin resistance. A Y mice have a mutation on
chromosome 2 at the agouti locus. All surviving mice with the AY mutation are heterozygous for
the AY mutation. Mice that are homozygous for the AY mutation will result in embryonic
lethality before implantation (Iwatsuka, Shino, & Suzuoki, 1970). This mutation causes these
mice to overexpress agouti which results in a completely yellow coat color and a genetically
obese and diabetic mouse model. AY mice are prone to yellow obese syndrome which consists of
obesity, hyperglycemia, hyperinsulinemia, increased tumor incidence and increased skeletal and
muscle growth (Miltenberger, Mynatt, Wilkinson, & Woychik, 1997). It is common for A Y mice
to become infertile a few months after birth (Iwatsuka et al., 1970). In a preferential
macronutrient study, AY mice consumed higher amounts of fat than carbohydrate and protein.
This preference for fat could explain their increase in overall body fat content. Antagonists to the
melanocortin receptors (MC-Rs) or increased palatability could be credited for the preferential
consumption of fat in these mice. Liver weights for A Y mice, expressed as absolute weight or as
percent of body weight, were both found to be significantly heavier relative to control mice.
(Koegler, Schafffhauser, Mynatt, York, & Bary, 1999)
The agouti gene locus manages the distribution of eumelanin (brown and black) and
pheomelanin (red and yellow) for coat pigmentation. Agouti is a small protein made up of 131
amino acids (Wang & Majzoub, 2011). Agouti antagonizes α-melanocyte-stimulating hormone
(α-MSH) by blocking the actions of follicular melanocytes at the melanocortin 1 receptor
(MC1R). MC1R is a highly expressed G protein-coupled receptor found in melanocytes.
Melanocytes are cells responsible for pigment production. Under normal circumstances, α-MSH
would activate MC1R which would elevate cAMP levels and increase the production of
eumelanin. If agouti is present, it serves as an antagonist to MC1R which results in decreased
eumelanin and increased pheomelanin production (Nachman, Hoekstra, & D'Agostino, 2003).
This is what causes the phenotypic yellow coat color observed in heterozygous A Y mice. Agouti
can also serve as an antagonist to neural melanocortin receptors, MC4R and MC3R; however,
the interaction with MC3R is notably weaker (Wang & Majzoub, 2011). The melanocortin
system only has two known antagonists, agouti related protein (AGRP) and agouti (Tao, 2010).
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The paracrine signaling molecule known as agouti related protein (AGRP) is known to
regulate body weight. It serves as an antagonist to both neural melanocortin receptors, MC3R
and MC4R (Ollmann, 1998). It is expressed at highest amounts in the hypothalamus and adrenal
medulla. Lower levels of expression can be seen in the testis, lung and kidney (Wang &
Majzoub, 2011). Normally, leptin is released from adipose tissue and it acts upon melanocortin
neurons or AGRP neurons. This results in increased α-MSH and decreased AGRP. When αMSH binds MC4R, it inhibits food intake and increases energy expenditure. If AGRP blocks αMSH, food intake is increased and energy expenditure decreases (Dutia et al., 2013). At the
melanocortin receptor in the skin, MC1R, agouti blocks α-MSH from binding which results in a
yellow coat color. Since agouti can also antagonize MC4R and MC3R, it also has the ability to
block neural α-MSH. Therefore, a ubiquitous promoter driving the overexpression of agouti
results in a yellow coat color when the α-MSH in the skin is blocked by agouti as well as obesity
when the α-MSH in the brain is blocked by agouti. The phenotype associated with the
heterozygous lethal yellow (Ay) mutated mice can be explained by the overexpression of agouti;
however, the embryonic lethality found in mice that are homozygous for this mutation is caused
by the deletion of another gene.
The AY mutation is brought about by a 170 kb excision which removes a gene known as
Raly which is positioned upstream of the agouti locus. The Raly gene promoter and first
noncoding exon is all that remains after the deletion (Michaud et al., 1994). Essentially, what
happens is Raly’s promoter splices into the open reading frame of the agouti gene and begins to
drive the expression of agouti which results in ubiquitous overexpression of agouti. The excision
of the Raly gene is believed to be the cause of lethality in mice that are homozygous for this
mutation (Michaud et al., 1994). The genetically induced obesity and insulin resistance found in
these mice makes for a desirable model for obesogenic and diabetic research.
1.3. The Skeletal Muscle Specific Cpt1bm-/- Knock Out Mice
The enzyme Cpt1 resides in the outer mitochondrial membrane and is responsible for
catalyzing the reaction necessary for the transport of long chain fatty acids into the inner
mitochondrial membrane where beta oxidation can occur. The Cpt1 isoform of interest is Cpt1b
since this is the form found in skeletal muscle. Cpt1b is one of three isoforms with the other two
being Cpt1a and Cpt1c. Cpt1a is expressed ubiquitously with exceptions being skeletal muscle
and brown adipose tissue. Its largest expression is found in the liver. Cpt1b is expressed in heart,
skeletal muscle and brown adipose tissue and Cpt1c can be found in the brain and testes (Rufer,
Thoma, & Hennig, 2009). When Cpt1b is knocked out in skeletal muscle, long chain fatty acylCoAs cannot be conjugated to L-carnitine. Since acyl-CoA cannot cross into the mitochondrial
matrix through simple diffusion, fatty acid beta oxidation is inhibited in skeletal muscle (Cobb &
Dukes, 1998).
Through the use of transgenes and mouse genome manipulation, knock out mouse
models are designed to allow for a deeper understanding of diabetes and obesity. The Cpt1b
muscle specific knock out in this study was achieved by crossing mice with floxed alleles of
Cpt1b to Mlc1f-Cre transgenic mice for skeletal muscle specific deletion of Cpt1b, but not
cardiac tissue (Shawna E. Wicks et al., 2015). Previous studies using this mouse model noted
that despite ectopic lipid accumulation in muscle, Cpt1b -/- mice maintained insulin sensitivity
while on a moderate fat (25% kcal) breeder chow diet (S. E. Wicks et al., 2015). Additionally,
skeletal muscle specific Cptlbm-/- mice had improved glucose uptake along with induced Fgf21
2

expression in muscle. A double knockout mouse model of Cpt1b and Fgf21 showed a partial
negation in improved glucose utilization in comparison to Cpt1b knock outs. Fgf21 appeared to
be partially responsible for the increase in glucose utilization in a manner that was independent
of the stress signaling pathway but dependent on AMPK and Akt1 signaling (Vandanmagsar et
al., 2016).
1.4. Controversial Research Regarding Inhibition and Upregulation of B-Oxidation in
Skeletal Muscle
Whether overexpression or inhibition of Cpt1 in skeletal muscle is needed to improve
insulin resistance is a controversial topic with literature supporting both concepts. Cpt1
overexpression in skeletal muscle was found to be sufficient for mitigating lipid-induced insulin
resistance in a rat study. Overexpression was achieved through in vivo electro transfer of a
purified Cpt1 plasmid via direct injection into the tibialis anterior of rats. Extensor digitorum
longus (EDL) was the muscle used for measuring glucose uptake due to its close proximity with
the tibialis anterior. Overexpression of Cpt1 in the EDL of rats fed high fat diet for a 4-week
period enhanced insulin stimulated glucose uptake to similar levels seen in the control rats fed a
chow diet (Bruce et al., 2009). Similar results were found in a study where increased B-oxidation
in muscle cells was enough to increase glucose metabolism stimulated by insulin and protect
against fatty acid induced insulin resistance. B-oxidation in myocytes was enhanced by
transducing myotubules with an adenovirus encoding Cpt1. They proposed that enhanced Boxidation in muscle was enough to exert an insulin sensitizing effect despite no change in
intramyocellular lipid accumulation (Perdomo et al., 2004). A study using myotubules found
overexpression of Cpt1 protected against fatty acid induced insulin resistance. This
overexpression lead to a reduction in the accumulation of lipid in muscle tissue thus diminishing
the likelihood of fulfilling the lipotoxic model of skeletal muscle insulin resistance hypothesis
(Sebastian, Herrero, Serra, Asins, & Hegardt, 2007).
Contrary to the findings above, another study found deficiency in Cpt1b protected mice
from diet induced obesity. The animals in this study had a global heterozygous Cpt1b +/- knockout
and therefore showed that partial inhibition of Cpt1b was sufficient to protect from insulin
resistance when fed a high fat diet for up to 5 months (Kim, He, et al., 2014). A later study found
the partial knock out mice developed severe insulin resistance after 7 months on the high fat diet,
providing further justification for our homozygous knock out model (Kim, Moore, et al., 2014).
Oxfenicine, a Cpt1 inhibitor, was used to hinder Cpt1 activity consequently alleviating insulin
resistance associated with diet induced obesity. Findings included increased carbohydrate
utilization and improvement in insulin signaling in skeletal muscle, proposing a possible Randle
Cycle in skeletal muscle (Keung et al., 2013). Malonyl-CoA decarboxylase (mcd -/-) knockout
mice were generated to inhibit fat catabolism in skeletal muscle. Malonyl-CoA decarboxylase
(MCD) is the enzyme that converts malonyl CoA to acetyl CoA and CO 2. In doing so, MCD
prevents the buildup of malonyl CoA, a known inhibitor of Cpt1. Therefore, when MCD is
knocked out, malonyl CoA will build up and inhibit Cpt1 and thus fatty acid oxidation in skeletal
muscle. Results from this study showed mcd-/- mice resisted diet induced glucose intolerance
despite having higher than normal intramuscular levels of long-chain acyl-CoAs (Koves et al.,
2008).
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1.5. Existing Theories for Skeletal Muscle Insulin Resistance
This leads to discussion of two competing theories pertaining to skeletal muscle insulin
resistance. The first theory states that excess ectopic lipid buildup leads to insulin resistance
because lipid overload interferes with insulin signaling. Hardy et al. says the accumulation of
ectopic lipid in skeletal muscle may cause insulin resistance through the formation of toxic
intermediates; for example, saturated fats have presented evidence of increased ceramide
production, which seems to augment insulin resistance (Hardy, Czech, & Corvera, 2012). A
buildup of diacylglycerols (DAGs) has been shown to activate isoforms of novel protein kinase
C which leads to phosphorylation of insulin receptor substrate-1 (IRS-1), resulting in impaired
downstream insulin signaling. The term “lipotoxicity” has been coined to define the state in
which excess lipid accumulation leads to insulin resistance in skeletal muscle (Badin et al.,
2011).
The contending theory states that excess ectopic lipids are partially broken down by
mitochondria, and the incompletely broken-down intermediates are toxic, which then interfere
with insulin signaling. A study found skeletal muscle insulin resistance to be indicative of
elevated fatty acid catabolism rates which resulted in incomplete fatty acid B-oxidation and a
large portion of fatty acids entering the mitochondria resulting in only partial degradation.
Further characteristics of skeletal muscle insulin resistance from this study included debilitated
switching of fuel substrates between the fed-to-fasted transition (“metabolic inflexibility”) and a
deficiency in multiple Krebs cycle intermediates (Koves et al., 2008). Additionally, inhibition of
fatty acid transport into the mitochondria of skeletal muscle resulted in a rather remarkable
phenotype where mice remained insulin sensitive despite ectopic lipid accumulation in the
muscle (S. E. Wicks et al., 2015).
Since Cpt1b skeletal muscle specific knockout mouse models have been shown to have
ectopic lipids yet no insulin resistance, we favor the latter theory. Without Cpt1b the
mitochondria are not capable of breaking down fatty acids; therefore, the culprit for insulin
sensitivity interference may be the toxic incompletely broken-down intermediates rather than
ectopic lipid buildup.
Based off the data mentioned above regarding Cpt1 overexpression and insulin
sensitivity, increased capacity for breaking down lipids may also prevent the buildup of toxic
intermediates. However, some warn against the use of pharmacologic strategies geared toward
boosting B-oxidation to alleviate muscle insulin resistance, suggesting fatty acids must penetrate
muscle mitochondria in order to exert insulin-desensitizing effects. Their evidence proposes
obesity-associated glucose intolerance arising from metabolic overload of muscle mitochondria
which could potentially result from excessive B-oxidation (Koves et al., 2008). Another study
found similar results against the use of excessive B-oxidation for ameliorating skeletal muscle
insulin resistance. While studying gain-and-loss-of-function of peroxisome proliferator-activated
receptor-α (PPAR-α) in regards to the development of insulin resistance, transgenic mice
overexpressing PPAR-α in muscle resulted in increased rates of fatty acid oxidation along with
glucose intolerance. PPAR-α null mice were protected from insulin resistance. Oxfenicine, an
inhibitor of skeletal muscle Cpt1, was administered to the transgenic mice overexpressing
PPAR-α, resulting in lipid accumulation in skeletal myocytes and improved glucose tolerance
(Finck et al., 2005). Herein, we align with the hypothesis for protection from skeletal muscle
insulin resistance with reduced rather than excessive fatty acid oxidation.
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1.6. Combinational Approach in this Study
The overall objective of this project is to determine if inhibiting skeletal muscle
mitochondrial fatty acid oxidation can help improve insulin resistance and weight loss in a
genetically obese and diabetic mouse model. The hypothesis made states that carnitine palmitoyl
transferase (Cpt1b) inhibition specifically in skeletal muscle could improve fat mass and blood
glucose levels in a genetic mouse model of obesity and diabetes. In an attempt to further
understand how inhibiting fatty acid oxidation mediates insulin resistance and obesity, carnitine
palmitoyltransferase (Cpt1b) was knocked out in skeletal muscle of a genetically obese mouse
model known as lethal yellow (AY) mutated mice. Four genotypes were included: Control mice,
Cpt1bm-/- mice, AY mice and AY: Cpt1bm-/- mice with focus throughout being primarily on AY:
Cpt1bm-/- mice since the Cpt1bm-/- phenotype has been well established in prior studies (S. E.
Wicks et al., 2015) (Vandanmagsar et al., 2016; Warfel et al., 2016). All mice from this study
came from the C57BL/6 background.
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Methods
2.1. Animal Studies
Animal studies took place at Pennington Biomedical Research Center’s American
Association for the Accreditation of Laboratory Animal Care-approved facility, with mice
receiving a standard chow diet, comprised of 25% fat, 55% carbohydrate and 20% protein
(Mouse Chow Diet no. 5015; LabDiet). All procedures were in agreeance with the NIH Guide
for the Care and Use of Laboratory Animals and authorized by the Institutional Animal Care and
Use Committee. The majority of the mice used in this experiment were between the ages of 4 to
8 months of age unless stated differently.
2.2. Animal Procedures
Body composition (fluid, fat mass, lean mass) was measured using a Bruker NMR
Minispec (Bruker Corporation). Mice were weighed on a scale prior to each use of Minispec and
bodyweights were recorded in grams. Serum and plasma collections were performed by
submandibular bleed. Following a 4 hour fast, glucose tolerance tests (GTTs) were performed by
intraperitoneal injection of 10% D-glucose (40 mg of glucose per mouse). Blood glucose was
measured with a glucometer at 0, 20, 40 and 60 minutes via tail end snip. Insulin Tolerance tests
(ITTs) were performed while in the fed state, using an intraperitoneal dose of 0.04 units (U) per
mouse. Measurements were taken with a glucometer at 0, 20, 40 and 60 minutes via tail end snip.
2.3. Metabolic Profiling
ELISA kits were used for measurement of 4 hour fasted serum insulin (Ultra-Sensitive
Mouse Insulin ELISA kit; Crystal Chem, Inc. #90080) and Triglycerides (TAGs) (TriglycerideH; Wako Diagnostics) and fed serum FGF21 (BioVendors). Liver TAGs were also measured
(Triglyceride-H; Wako Diagnostics). Glycogen was measured in liver using a commercial kit
(65620; Abcam) with instructions provided by the manufacturer.
2.4. Hepatic Fluid Measurement
Tissues were collected and patted free of exogenous blood prior to being snap frozen in
liquid nitrogen. This procedure was precisely replicated for all livers collected. Aliquots ranging
from 20-100 mg were collected from each whole liver for this dehydration experiments. Each
aliquot was weighed before being placed in the NAPCO vacuum oven (model 5831). Samples
were left in the vacuum overnight with the temperature control set at a 2.5 and vacuum at ≈ 5
Hg. Desiccated samples were reweighed the next morning. The difference between the wet
weight and desiccated weight was recorded for each sample and perceived as fluid level. Next,
grams of fluid per grams of wet weight were determined by dividing the difference (fluid
amount) for each sample by the weight of the aliquot prior to dehydration for each sample. Total
fluid was determined by multiplying the value for grams of fluid per grams of wet weight for
each sample with the original whole liver weight recorded at necropsy for each sample.
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2.5. qRT-PCR
Total RNA from mouse tissue (snap frozen on liquid nitrogen at the collection) was
isolated using a RNeasy Mini Kit (Qiagen) and DNase was used to degrade DNA. cDNA
synthesized with the iScript cDNA synthesis kit was used for qRT-PCR with the SYBR Green
system (Bio-Rad). qRT-PCR was conducted using DDCT assay. Mouse cyclophilin B was used
as the housekeeping-gene control for normalization of gene expression. Previously our lab
demonstrated that all target and control genes showed appropriate amplification using standard
curves. Primer details are provided in table 1.
2.6. Histology
Liver from mice were harvested and fixed with formalin. Then the tissues were
embedded in paraffin and sectioned and stained with H&E at the Cell Biology and Bioimaging
Core Facility at Pennington Biomedical Research Center. Images were viewed at a magnification
of 5x using NDP.view2 software.
2.7. Generation of Skeletal Muscle-Specific Cpt1b KO Mice
Knock out mice were achieved through the use of the cre-lox system. This technology
requires the generation of a cre-lox mouse via breeding. Typically, this is produced by mating a
mouse positive for cre with a mouse with lox P sights flanking the gene of interest. Cre serves as
a recombinase which is guided by a specific promoter which in this case is Mlc1f (Laboratory,
2006). The Mlc1f-Cre transgene is used to ablate Cpt1b specifically in skeletal muscle but it
remains highly expressed in cardiac tissue. This is because the Mlc1f promoter is specific for
skeletal muscle. Mlc1f is one of two independent promoters located at the myosin light chain
locus. These promoters are differentially activated during skeletal muscle development. The
second promoter is known as Mlc3f. The Mlc1f promoter is used for skeletal muscle specific
knock downs because the Mlc3f promoter has low level expression in the left atria and ventricle
of mouse cardiac tissue (Kelly, Alonso, Tajbakhsh, Cossu, & Buckingham, 1995). When the cre
recombinase mouse is bred with the flanked lox P gene of interest mouse, cre will cut half of
each lox P site resulting in the excision of the gene of interest from the genome and
recombination of the remaining lox P halves. For this experiment, cre positive mice were bred to
floxed Cpt1b mice in order to achieve a skeletal muscle specific Cpt1b knock out. Cpt1b muscle
specific knock out mice were achieved by breeding Mlc1f-Cre recombinase mice (from Gerald
Bothe, Wadsworth Center, Albany, NY) that were backcrossed for 10 generations to C57BL6
mice; therefore, all mice are from the C57BL6 background. All chimeric mouse production and
gene targeting was executed by the Transgenic Core at Pennington Biomedical Research Center.
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Table 1. Primers and Sequences. This is a comprehensive list of forward and reverse primers
used in this study.
Gene Symbol Reference
Sequencing ID
Hadha
NM_178878
Ech1

NM_016772

Bckdha

NM_007533

Bcat2

NM_001243052

Cd36

NM_001159555

Fatp1

NM_011977

Fabp3

NM_010174

Plin5

NM_001077348

Acox1

NM_015729

Fgf21

NM_020013

Cs

NM_026444

Cyclophilin NM_011149
Pdha1

NM_008810

Gdf15

NM_ 23886

Acaca

NM_ 107476

Fasn

NM_ 14104

Scd1

NM_ 20249

Cpt1a

NM_ 12894

Pck1

NM_ 18534

Forward Primer

Reverse Primer

TGACGCTGGTTATCTTGCT ATCAGGGCCTTCGATTCTTT
G
TCGCTACTGCACTCAGGA AGCAGCCAAGCCCATATCTA
TG
GTGGGATGAGGAACAGGA CTTGGGTTCGGCTTTAGCTT
GA
CGCTTCCAGAAGGAACTG CACACCCGAAACATCCAATC
AA
GCAAAGAACAGCAGCAA TCCTCGGGGTCCTGAGTTAT
AATC
GGTGGTACTGCGCAAGAA AGCGGCAGATTTCACCTATG
GT
GACGAGGTGACAGCAGAT CTGCACATGGATGAGTTTGC
GA
CTTCCTGCCCATGACTGA ACCCCAGACGCACAAAGTAG
G
CTTCGAGGGGGAGAACAC CCCGACTGAACCTGGTCATA
T
TTCTTTGCCAACAGCCAG GTCCTCCAGCAGCAGTTCTC
AT
CGGGAGGGCAGCAGTATC ACCACCCTCATGGTCACTATGGA
GG
TG
TCCATCGTGTCATCAAGG CTCATCTGGGAAGCGCTCA
ACTT
GGTTGCTTCCCGTAATTTT GTGAGCACTGTGGTGACTGG
G
GCTGTCCGGATACTCAGT GTAGGCTTCGGGGAGACC
CC
ATGGTTGAGTGGGTTTTTT CCTAACCTGGCTCTGCCAACT
GACTAT
GATCCTGGAACGAGAACA TCGTGTCAGTAGCCGAGTCA
CGAT
CCGGGAGAATATCCTGGT TAGTCGAAGGGGAAGGTGTG
TT
CATGATTGCAAAGATCAA CTTGACATGCGGCCAGTG
TCGG
GGTGTCCCCCTTGTCTATG ATCTTGCCCTTGTGTTCTGCA
AAG
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2.8. Generation of Skeletal Muscle-Specific Cpt1b KO and A Y Mutated Mice
The AY:Cpt1bm-/- mice are double mutated and may be referred to as Double Mutants
(DMut Mice). The Cpt1b knock out mice were generated as described above. The Cpt1b knock
out mice were then crossed with AY mice (Jackson Laboratory) in order to achieve the double
mutated mice.
2.9. Confirmation of Genotype
Mouse DNA is obtained from tail end snips or ear punches. Snips are digested using a tail
lysis buffer. Following digestion, DNA is isolated through a series of separations with columns
using centrifugation. DNA is amplified via polymerase chain reaction (PCR), then run on an
agarose gel. Upon completion of electrophoresis, the gel is imaged using the Image Lab 4.0.1
Software.

Figure 1. Genotyping for Cre and Cpt1b. This gel image demonstrates how mice are genotyped
for cre recombinase and floxed Cpt1b.
Knock out mice are confirmed by checking for cre recombinase and lox P sites. When
checking for cre, an internal processing control (IPC) is used in order to reduce the chances of
false negatives. Therefore, all mice should show a band at 320bp which is indicative of the IPC.
The IPC amplicon is added to the extracted DNA for each sample before the DNA is added to
the well of the gel. For detection of the cre gene, forward and reverse primers for the cre gene are
9

used to produce amplicons with the size of 166 bp. Therefore, cre positive mice will show an
additional band at 166bp and cre negative mice will show nothing other than the IPC at 320bp.
When checking for lox P sites, forward and reverse primers for the Cpt1b gene with the start of
the primers coming before the insertion points of loxP are used. Control mice with no lox P sites
will show one band at 360bp. Floxed mice (mice with target DNA sequence sandwiched between
2 lox P sites) will show one band at 460bp. Heterozygous mice will show one band at 360bp and
another band at 460bp.
2.10. Sable Systems Promethion
Mice were put in the Sable Systems International promethion for 1 week. Food and water
uptake and respiratory quotient measurements were taken every 5 minutes while in the
promethion chamber.
2.11. Statistical Analysis
Data were analyzed by t test if normally distributed with an n of at least 8. If data failed
D’Agostino-Pearson test for normality or had an n less than 8, the Mann Whitney test was run.
Tests were run using GraphPad Prism 7 software. JMP software from SAS was used for the
linear regression analysis. The P value was set at <0.05 a priori.
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Results
When mitochondrial fatty acid oxidation is inhibited in skeletal muscle by knocking out
Cpt1b, the expression of genes involved in mitochondrial fatty acid oxidation is expected to be
upregulated in skeletal muscle. This model would also suggest a build-up of lipid in skeletal
muscle. To confirm these expectations, the expression of genes involved in mitochondrial fatty
acid oxidation, transport, binding and storage were all measured.
3.1. Cpt1b Deficiency Encapsulates a Model of Lipid Accumulation and FAO Impairment.
Increase in the Release of Fatty Acids in Circulation
Impaired fatty acid oxidation in skeletal muscle was achieved by knocking out Cpt1b, the
rate-limiting enzyme of the long-chain fatty acid beta-oxidation (FAO) pathway in muscle
mitochondria. Expression of genes involved in mitochondrial fatty acid oxidation, HydroxyacylCoA dehydrogenase and Enoyl-CoA hydratase 1 (Hadha and Ech1), were significantly elevated
in the gastrocnemius of AY:Cpt1bm-/- mice relative to control mice (Figure 2A). The Hadha gene
is responsible for constructing part of the enzyme complex referred to as mitochondrial
trifunctional protein. This complex consists of 3 enzymes which are all essential for fatty acid
oxidation. Ech1 enzyme functions in the auxiliary step of the fatty acid B-oxidation pathway. In
addition to this, expression of genes involved in fatty acid transport (Cd36 and Fatp1), binding
(Fabp3) and storage (Plin5) were also upregulated in the gastrocnemius of AY:Cpt1bm-/- mice
relative to controls and AY mice (Figure 2B and 2C). CD36, also known as fatty acid translocase,
is responsible for long-chain fatty acid transport in muscle cells. Fatty acid transport protein 1
(Fatp1) serves as an enhancer of cellular uptake of long-chain fatty acids. Fatty acid binding
protein 3 (Fabp3) is believed to participate in uptake, metabolism and transport of long-chain
fatty acids. Perilipin-5 (Plin5) coats the surface of lipid droplets and serves as a barrier which
provides increased storage capacity. Taken together, we believe this data displays skeletal
muscle specific ablation of Cpt1b as a model of FAO impairment and lipid accumulation in
genetically obese AY:Cpt1bm-/- mice.
A.)

B.)

fig cont’d
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C.)

Figure 2. Lipid Accumulation and FAO Impairment in Skeletal Muscle.
A.) Mitochondrial fatty acid oxidation genes are significantly elevated in A Y and AY:Cpt1bm-/mice relative to control mice. B.) Fatty acid transport, binding and storage genes are upregulated
in the gastrocnemius of AY:Cpt1bm-/- mice relative to control and AY mice. C.) Binding and
storage genes are upregulated in the gastrocnemius of A Y:Cpt1bm-/- mice relative to control and
AY mice. Significance was set at a p < 0.05. n=4-10.
With mitochondrial fatty acid oxidation (FAO) being inhibited in skeletal muscle, we
wanted to know if peroxisomal FAO was compensating for the lack of mitochondrial FAO. We
were also interested in seeing if other fuel sources were being used in place of fat. We decided to
measure the expression of genes involved with peroxisomal fatty acid oxidation and amino acid
catabolism.
3.2. Mitochondrial Biogenesis, Peroxisomal FAO and Amino Acid Catabolism are
Upregulated in Gastrocnemius of AY:Cpt1bm-/- Mice Relative to AY Mice
Skeletal muscle of AY:Cpt1bm-/- mice appears to become more heavily reliant on
peroxisomes for fatty acid oxidation. Peroxisomes are organelles that specialize in the oxidation
of a wide variety of fatty acids. Acyl-coenzyme A oxidase 1 (Acox1) is an enzyme responsible
for performing B-oxidation of fatty acids in the peroxisomes of cells and its expression was
found to be upregulated in the gastrocnemius of A Y:Cpt1bm-/- mice (Figure 3A). Additionally,
skeletal muscle of AY:Cpt1bm-/- mice appear to use alternative sources of fuel for energy. For
example, branched-chain alpha-keto acid dehydrogenase and branched chain amino acid
transaminase 2 (Bckdha1 and Bcat2), are both involved in the catabolism of branched chain
amino acids and are found to be upregulated in the gastrocnemius of A Y:Cpt1bm-/- mice (Figure
3B).
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A.)

B.)

Figure 3. Adaptations Made in Skeletal Muscle
A.) Peroxisomal fatty acid oxidation is significantly elevated in the A Y:Cpt1bm-/- mice relative to
control and AY mice. B.) Amino acid oxidation is significantly upregulated in A Y:Cpt1bm-/- mice
relative to controls and AY mice. Significance was set at a p < 0.05. n=4-10.
We were interested in looking at caloric intake for these mice. Calorimetry data were
obtained by housing mice in single-caged promethion chambers for a week long period. Food
and water consumption were measured. Cpt1bm-/- mice have previously been shown to eat
significantly less relative to control mice when fed a 25% fat diet (Warfel et al., 2017).
Therefore, we wanted to see if AY:Cpt1bm-/- mice behaved similarly when fed a 25% diet.
3.3. AY Mice ate more Food and Drink more Water Relative to AY:Cpt1bm-/- Mice
AY mice ate significantly more food than the A Y:Cpt1bm-/- mice (Figure 4A). AY mice
also consumed significantly more water relative to Control and A Y:Cpt1bm-/- mice (Figure 4B).
A.)

B.)

Figure 4. Food and Water Intake
A.) AY mice consumed significantly higher amounts of food relative to A Y:Cpt1bm-/- mice. B.)
Water intake for AY mice was also significantly higher relative to Control and AY:Cpt1bm-/- mice.
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Body composition was measured over an 18-week period using a Bruker NMR Minispec.
Lean mass was lower in the AY:Cpt1bm-/- mice relative to AY mice which may explain their
decrease in food and water intake. Previously, Cpt1b m-/- mice were shown to have a decrease in
food intake relative to controls when fed a 25% fat diet. This decrease in food intake was due to
a decrease in lean mass. Cpt1bm-/- had less lean mass; therefore, they were consuming less
energy. However, Cpt1bm-/- were shown to maintain control levels for lean mass when fed a 10%
diet. It was suggested that skeletal muscle Cpt1b knock out may cause an aversion to fat in the
diet (Warfel et al., 2017).
3.4. Compared to AY Mice, AY:Cpt1bm-/- Mice Have Only Numerically Lower Body Weight,
Fat Mass and Lean Mass
Compared to AY mice, AY:Cpt1bm-/- mice had numerically lower body weights, but
differences were not significant (Figure 5A). As the length of the study increased in weeks, this
numerical difference increased. Significance was likely not obtained because of the relatively
small number of mice and variability. Fat mass for AY:Cpt1bm-/- mice had a numerical difference
with lower levels than for AY mice only for the eighteenth week (Figure 5B). Lean mass for
AY:Cpt1bm-/- mice was also numerically lower than for AY mice from ten through eighteen weeks
of the study (Figure 5C). These results indicate that studies with greater numbers of mice may
result in statistical differences.
A.)

B.)

C.)

Figure 5. Food and Water Intake
A.) Over an 18 week timeline, AY:Cpt1bm-/- mice had numerically lower body weight in
comparison to AY mice; however, no significant difference was noted between groups. Both
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groups were significantly heavier than Control mice. B.) Fat mass for the A Y:Cpt1bm-/- mice was
also numerically below AY mice. Both groups had significantly more fat mass than Control mice.
C.) Lean mass for the AY:Cpt1bm-/- mice was numerically lower than AY mice. AY mice had
significantly more lean mass than Control mice. Significance was set at a p < 0.05. n=6-13.
Despite minimal changes in fat mass and body weight for A Y:Cpt1bm-/- mice relative to
AY mice, we did find a rather remarkable improvement in glucose clearance and insulin
sensitivity. Taken together, these findings suggest a metabolically healthy, yet obese state for the
AY:Cpt1bm-/- mouse model.
3.5. AY:Cpt1bm-/- Mice Have Improved Insulin Resistance and Glucose Clearance
Compared to AY Mice
Remarkably, despite minimal changes in body weight and composition, A Y:Cpt1bm-/mice performed significantly better on glucose clearance and insulin sensitivity tests. At 13weeks-of-age, AY:Cpt1bm-/- mice achieved significantly better results relative to AY mice during
a glucose tolerance test (GTT) (Figure 6A). Performance during an insulin tolerance test (ITT) at
14-weeks-of-age improved significantly in AY:Cpt1bm-/- mice relative to AY mice (Figure 6B).
AY:Cpt1bm-/- mice managed to return to control levels for both tests (GTT and ITT) while blood
glucose levels remained elevated in AY mice. Insulin levels were checked in 32-week-old mice in
the fasted state and AY mice had significantly higher fasted insulin levels relative to control and
AY:Cpt1bm-/- mice. Insulin levels for AY:Cpt1bm-/- mice were returned to control levels (Figure
6C).
A.)

B.)

fig cont’d
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C.)

Figure 6. Glucose Tolerance and Insulin Sensitivity
A.) AY:Cpt1bm-/- mice performed significantly better on glucose tolerance testing (GTT) in
comparison to AY mice at 13 weeks of age. B.) At 14 weeks of age, A Y:Cpt1bm-/- mice performed
significantly better during insulin tolerance testing compared to A Y mice. C.) Insulin was
measured in serum using an ultra-sensitive mouse insulin ELISA kit. Samples were from 32week-old mice in the fasted state. AY:Cpt1bm-/- mice had significantly less circulating insulin in
comparison to AY mice. Significance was set at a p < 0.05. n=4-13.
In an attempt to better understand the reason for these improvements in glucose clearance
and insulin sensitivity, the expression of Fgf21 and Pgc1a was measured in skeletal muscle.
Fgf21 was measured because it has been shown previously to be contributing to the improvement
in glucose clearance and insulin sensitivity seen in the Cpt1b m-/- mice. Pgc1a was measured to
assess if mitochondrial biogenesis was upregulated in skeletal muscle. If more mitochondria
were present, this may offer an explanation for improved glucose clearance.
3.6. AY:Cpt1bm-/- Mice Have Elevated Fgf21 and Pgc1a in Skeletal Muscle Relative to A Y
Mice.
Fibroblast growth factor 21 (Fgf21) is elevated in the gastrocnemius of A Y:Cpt1bm-/mice (Figure 6A). Fgf21 has been shown as being partially responsible for enhanced glucose
clearance in Cpt1bm-/- mice. With a similar result seen in AY:Cpt1bm-/- mice, we assume Fgf21
likely plays a role in the insulin sensitizing effect seen in the double mutant mouse model.
Cpt1bm-/- mice appear to acclimate to the muscle specific ablation with favorable adaptations
such as increased mitochondrial biogenesis. Peroxisome proliferator-activated receptor gamma
coactivator 1-alpha, Pgc1a, is a transcriptional coactivator that serves as a central inducer in
mitochondrial biogenesis and it is significantly elevated in gastrocnemius muscle of A Y:Cpt1bm-/mice relative to control and AY mice (Figure 7B).
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A.)

B.)

Figure 7. Skeletal Muscle Fgf21 and Pgc1a
A.) At 32 weeks of age, Fgf21 expression in gastrocnemius is significantly elevated in
AY:Cpt1bm-/- mice relative to Control and AY mice. B.) Mitochondrial biogenesis is significantly
upregulated in the AY:Cpt1bm-/- mice relative to control and AY mice. Significance was set at a p
< 0.05. n=4-9.
In addition to improving glucose clearance and insulin sensitivity, Fgf21 is known for
having a paradoxical effect in which its levels are elevated in the circulation of obese mice.
Some have proposed obesity as an Fgf21 resistant state. We decided to evaluate this in our mice
by using an Fgf21 Elisa kit to measure levels in fed serum. Since levels in the AY:Cpt1bm-/- mice
were found to be numerically lower than A Y levels, the skeletal muscle Cpt1b knock out may be
responsible for lower levels in circulation and suggestive of improved overall utilization of
Fgf21.
3.7. Fgf21 is Elevated in Serum of 32 Week Old AY:Cpt1bm-/- Mice in the Fed State Relative
to Control Mice, but Less than AY Mice
Fgf21 was found to be significantly elevated in the serum of AY mice in the fed state
relative to control mice (Figure 8). This elevation in serum may be indicative of Fgf21 resistance
in the genetically obese AY mice. As seen in Figure 7, the Fgf21 in fed serum of AY mice does
not appear to be coming from skeletal muscle. Rather, the primary source of Fgf21 in AY mice
appears to be from hepatic production. Fgf21 was elevated in the gastrocnemius and liver for
AY:Cpt1bm-/- mice; however, Fgf21 in fed serum was not significantly elevated in AY:Cpt1bm-/mice. Therefore, muscle specific knockout of Cpt1b may help avoid Fgf21 resistance and
promote insulin sensitivity.
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Figure 8. Fgf21 in Circulation
Fgf21 is increased in serum of 32 week old AY:Cpt1bm-/- mice relative to Control, but decreased
relative to AY mice, which could suggest Fgf21 resistance in AY mice, while not in AY:Cpt1bm-/mice. Significance was set at a p < 0.05. n=3-9.
While improvements in glucose clearance and insulin sensitivity are heavily notable in
the AY:Cpt1bm-/- mice, we also observed a significant decrease in their liver weights relative to
AY mice. This decrease in weight could be suggestive of improved hepatic health relative to A Y
mice. Further investigation will be needed to confirm this assumption.
3.8. Liver Weight is Decreased in AY:Cpt1bm-/- Mice Relative to AY Mice
Liver weights were drastically decreased in AY:Cpt1bm-/- mice relative to AY mice (Figure
9). Differences in weights are further discussed in Figure 10.

Figure 9. Liver Weight
Liver weights of AY:Cpt1bm-/- mice were significantly lower than liver weights of AY mice.
Significance was set at a p < 0.05. n=4-10.
With liver weight being significantly lower in AY:Cpt1bm-/- mice relative to AY mice, we
began to wonder what was accounting for this difference in weight. Since liver is an important
18

storage site for glycogen, we decided to assess hepatic glycogen levels to see if storage was
depleted in the livers of AY:Cpt1bm-/- mice relative to AY mice. We also assumed the liver may
be compensating for the loss of fatty acid oxidation in the muscle and have less ectopic fat as a
result. We decided to measure hepatic triglyceride levels. Additionally, lipid droplets were
viewed in liver samples that were embedded in paraffin and sectioned and stained with H&E at
the Cell Biology and Bioimaging Core Facility at Pennington Biomedical Research Center.
3.9. Liver Glycogen and Triglycerides are Numerically Decreased in A Y:Cpt1bm-/- Mice
Relative to AY Mice According to Chemical Analyses, but Histology Samples Demonstrate
Lower Fat Mass
Triglycerides in the liver of 32-week-old mice were significantly elevated in A Y mice
relative to Control. Triglyceride levels in AY:Cpt1bm-/- mice were not significantly elevated
relative to Control mice; however, the levels were not significantly less than A Y mice.
Triglycerides in the liver of AY:Cpt1bm-/- mice were numerically lower than for AY mice with the
p value equaling 0.1531 (Figure 10A). Hepatic glycogen levels followed a similar trend between
AY and AY:Cpt1bm-/- mice with AY:Cpt1bm-/- mice having lower glycogen amounts than AY mice
without reaching significance (Figure 10B). The p value between these two groups was p =
0.0952. While neither hepatic triglyceride or glycogen levels showed statistically significant
differences between AY and AY:Cpt1bm-/- mice, AY:Cpt1bm-/- mice had numerically lower
amounts and these numerical differences combined to result in a statistically significant
difference in liver weight. Histology samples also show less ectopic lipid in the livers of
AY:Cpt1bm-/- mice relative to AY mice (Figure 10C). Triglyceride content provides nonconclusive evidence that fats are decreased in AY:Cpt1bm-/- liver relative to AY liver; however,
other tissue levels such as white adipose, cholesterol and ceramide fat species still need to be
quantified.
A.)

B.)

fig cont’d
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C.)

Figure 10. Hepatic Triglycerides and Glycogen Levels and Histology Images
A.) Liver triglycerides levels were numerically lower in the livers of A Y:Cpt1bm-/- mice when
compared to liver triglycerides of AY mice; however, there was no statistical significance. B.)
Liver glycogen levels were also lower in AY:Cpt1bm-/- mice when compared to liver glycogen
levels of AY mice; however, there was also no statistical significance. C.) Liver histology images
(5x magnification) show more ectopic fat accumulation in the A Y mice relative to the
AY:Cpt1bm-/- mice. Significance was set at a p < 0.05. n=3-8.
While triglyceride and glycogen levels were numerically lower in A Y:Cpt1bm-/- mice
relative to AY mice, we did not think this was enough to account for the difference in liver
weights. Therefore, we decided to assess hepatic fluid levels as well.
3.10. Liver Contains Less Fluid Mass in AY:Cpt1bm-/- Mice Relative to AY Mice
In addition to hepatic triglyceride and glycogen levels being numerically lower in
A :Cpt1bm-/- mice compared to AY mice, hepatic fluid levels were significantly greater for AY
mice (Figure 11A). A correlation plot between fluid and triglyceride + glycogen content
generated an R2 value of 0.5; therefore, numerically greater triglyceride and glycogen amounts
appear to promote greater fluid retention (Figure 11B).
Y
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A.)

B.)

Figure 11. Hepatic Fluid and Fluid Retention Correlation Plot
A.) Liver fluid levels of AY:Cpt1bm-/- mice were significantly less than liver fluid levels of A Y
mice. B.) Correlation plot between triglycerides + glycogen and fluid had a R 2 value of 0.5.
Significance was set at a p < 0.05. n=4-10.
As seen previously in Figure 10C, histology images seem to reveal lower amounts of
ectopic fat in the livers of AY:Cpt1bm-/- mice relative to AY mice. To further assess this finding,
we decided to measure the expression of several genes involved in fatty acid synthesis.
3.11. Fatty Acid Synthesis Pathways Are Decreased in the Liver of A Y:Cpt1bm-/- Mice
Relative to AY Mice
Expression of enzymes involved in fatty acid synthesis was significantly upregulated in
the liver of AY mice relative to Control and AY:Cpt1bm-/- mice at 16-weeks-of-age. Acetyl-CoA
carboxylase (Acaca), the enzyme responsible for catalyzing the carboxylation of acetyl-CoA to
malonyl-CoA, is significantly upregulated in the liver of AY mice relative to Control mice at 16weeks-of-age. It is also increased in AY:Cpt1bm-/- mice relative to Control mice; however,
AY:Cpt1bm-/- expression trends less than AY mice (Figure 12A). Fatty acid synthase (Fasn), the
enzyme involved with catalyzing the synthesis of palmitate from acetyl-CoA and malonyl-CoA,
is significantly upregulated in the livers of AY mice relative to Control and AY:Cpt1bm-/- mice at
16-weeks-of-age (Figure 12B). Stearoyl-CoA desaturase (Scd1), the enzyme primarily
responsible for the synthesis of oleic acid, is upregulated in the liver of A Y mice relative to
Control and AY:Cpt1bm-/- mice at 16-weeks-of-age (Figure 12C). At 32-weeks-of-age, expression
of enzymes involved in fatty acid synthesis (Fasn and Scd1) were numerically greater in livers of
AY mice relative to Control and AY:Cpt1bm-/- mice (Figure 12D and 12E). However, Acaca was
significantly elevated in AY mice relative to Control mice, but only numerically higher than
AY:Cpt1bm-/- mice at 32-weeks-of-age (Figure 12F). Expression of these enzymes appears to
increase with age for all groups with upregulation occurring earlier in A Y mice. Expression
appears to remain higher in AY mice relative to all groups despite age. However, for the most
part, the higher amounts were not significantly different. While not significant (likely due to low
n with relatively high variability), these data may still be suggestive of elevated fatty acid
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synthesis in the livers of AY mice relative to AY:Cpt1bm-/- mice. Additional studies with a larger
number of mice per group are needed to confirm elevated levels in A Y mice at 32 weeks of age.
A.)

C.)

E.)

B.)

D.)

F.)

Figure 12. Hepatic Fatty Acid Synthesis
A.) Acetyl-CoA carboxylase alpha (Acaca) is significantly elevated in livers of 16-week-old AY
mice relative to Control and AY:Cpt1bm-/- mice. Acaca is also significantly elevated in
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AY:Cpt1bm-/- mice relative to Control. B.) Fatty acid synthase (Fasn) is significantly elevated in
livers of 16-week-old AY mice relative to Control and AY:Cpt1bm-/- mice. C.) Stearoyl-CoA
Desaturase (Scd1) is significantly elevated in livers of 16-week-old A Y mice relative to Control
and AY:Cpt1bm-/- mice. These data may be suggestive of elevated fatty acid synthesis in the livers
of AY mice relative to AY:Cpt1bm-/- mice. D.) Hepatic Fasn was numerically higher in AY mice
relative to control and AY:Cpt1bm-/- at 32 weeks of age. E.) Hepatic Scd1 was numerically higher
in AY mice relative to control and AY:Cpt1bm-/- at 32 weeks of age. F.) Acaca is significantly
elevated in the livers of 32-week-old AY mice relative to Control mice and is numerically higher
in AY mice relative to AY:Cpt1bm-/- mice. Significance was set at a p < 0.05. n=4-9.
Additionally, we wanted to check if mitochondrial and peroxisomal fatty acid oxidation
was upregulated in the livers of AY:Cpt1bm-/- mice relative to AY mice. We decided to measure
hepatic gene expression of genes involved with mitochondrial and peroxisomal fatty acid
oxidation.
3.12. Hepatic Mitochondrial and Peroxisomal Fatty Acid Oxidation is Increased in the
Liver of AY:Cpt1bm-/- Mice Relative to AY Mice
A.)

B.)

C.)

D.)
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Figure 13. Hepatic Fatty Acid Oxidation
A.) Ech1 was significantly upregulated in the liver of A Y:Cpt1bm-/- mice relative to Control mice.
B.) Hadha was significantly upregulated in the liver of AY:Cpt1bm-/- mice relative to Control
mice. C.) Cpt1a was found to be was found to be significantly elevated in the liver of
AY:Cpt1bm-/- mice relative to Control and AY mice. D.) Acox1, involved with peroxisomal fatty
acid oxidation, was also found to be significantly elevated in the liver of A Y:Cpt1bm-/- mice
relative to Control and AY mice .
Mitochondrial and peroxisomal fatty acid oxidation may be elevated in the liver of
AY:Cpt1bm-/- mice to compensate for the inhibition of mitochondrial fatty acid oxidation in
skeletal muscle. Respiratory quotient (RQ) data obtained from the promethion chambers show
AY:Cpt1bm-/- mice maintaining lower RQ’s relative to AY mice (Figure 14). This RQ data appears
to indicate that AY:Cpt1bm-/- mice are burning more fat for fuel relative to A Y mice. Additionally,
genes involved with mitochondrial and peroxisomal fatty acids were found to be up in the liver
of AY:Cpt1bm-/- mice. Taken together, these data may suggest increased reliance on fat for fuel
and consequentially reduced ectopic fat in the liver of A Y:Cpt1bm-/- mice.
3.13. Respiratory Quotient is Lower for AY:Cpt1bm-/- Mice Relative to AY Mice
A.)

B.)

Figure 14. Respiratory Quotient

A.) The respiratory quotient for AY:Cpt1bm-/- mice remains lower than that of AY mice,
suggesting a higher dependence on fat as a fuel source. B.) This graph displays only RQ’s of A Y
and AY:Cpt1bm-/- mice.
In addition to a lower RQ and increased hepatic mitochondrial and peroxisomal fatty acid
oxidation, hepatic gluconeogenesis was also found to be elevated in the liver of A Y:Cpt1bm-/mice.
3.14. Based on an Increase in Amounts of the Major Regulatory Gene for Gluconeogenesis,
This Pathway for Glucose Synthesis Appears to be Increased in the Liver of A Y:Cpt1bm-/Mice Relative to AY Mice
Noteworthy, phosphoenolpyruvate carboxykinase (Pck1), the major regulatory
gluconeogenic enzyme, is significantly upregulated in 32-week-old liver of A Y:Cpt1bm-/- relative
to Control and AY mice (Figure 15). The reason for this is unknown but may indicate that they
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are making more glucose to supply it for skeletal muscle. Additionally, the A Y:Cpt1bm-/- mice
may also have an increased need for glucose for energy.
A).

Figure 15. Hepatic Gluconeogenesis
A.) Gluconeogenesis appears to be significantly elevated in the livers of A Y:Cpt1bm-/- mice in
comparison to AY mice. Significance was set at a p < 0.05. n=4-6.
Triglycerides were significantly reduced in the serum of A Y:Cpt1bm-/- mice relative to AY
mice. Hepatic triglycerides were not significantly different between groups (Figure 10A);
however, significantly less triglycerides are released into circulation for A Y:Cpt1bm-/- mice
relative to AY mice. Previous research has shown Gdf15 to increase the release of hepatic
triglycerides into circulation (Luan et al., 2019). Expression of Gdf15 was found to be
upregulated in the liver of AY mice relative to AY:Cpt1bm-/- mice and may explain the significant
increase in circulating triglycerides.
3.15. Gdf15 is Upregulated in the Liver of AY Mice Relative to All Groups and May
Explain the Increase in the Release of Fatty Acids in Circulation
At 16-weeks-of-age growth differentiation factor 15 (Gdf15) was significantly elevated in
AY mice relative to Control and AY:Cpt1bm-/- mice (Figure 16A). At 32-weeks-of-age, Gdf15 was
numerically higher than Control (p=0.054) and AY:Cpt1bm-/- mice; however, no significance was
noted (Figure 16B). Triglycerides in serum of mice fasted for 4-hours were significantly higher
in AY mice relative to Control and AY:Cpt1bm-/- mice. Levels for AY:Cpt1bm-/- mice were
significantly lower than for Control mice (Figure 16C). The elevated expression of hepatic Gdf15
in AY mice may be partially responsible for the increase in triglyceride circulation.
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A.)

B.)

C.)

Figure 16. Hepatic Gdf15 and Triglycerides in Circulation
A.) Hepatic Gdf15 expression in AY mice is significantly higher than for Control and AY:Cpt1bm/mice at 16-weeks of age. B.) Hepatic Gdf15 expression in AY mice is numerically higher than
for Control and AY:Cpt1bm-/- mice at 32-weeks of age. C.) Triglycerides in serum of mice fasted
for 4 hours was significantly lower in AY:Cpt1bm-/- mice relative to Control and AY mice.
Significance was set at a p < 0.05. n=4-10.

26

Table 2. Summary of Results.
Measurements
Promethion Data
Food Intake

Results
Relative to AY

AY:Cpt1bm-/-

↓
↓
↓

Water Intake
Respiratory Quotient

AY:Cpt1bm-/- Relative to AY

Muscle Metabolism mRNA
Mitochondrial Fatty Acid Oxidation

↑
↑
↑
↑
↑
↑

Fatty Acid Transport, Binding and Storage
Peroxisomal Fatty Acid Oxidation
Amino Acid Catabolism
Mitochondrial Biogenesis
Fgf21

AY:Cpt1bm-/- Relative to AY

Hepatic mRNA
Gluconeogenesis

↑
↓
↑
↓

Gdf15
Fatty Acid Oxidation
Fatty Acid Synthesis

AY:Cpt1bm-/- Relative to AY

Metabolic Health
Improved Glucose Utilization
Improved Insulin Sensitivity
Decreased Body Weight
Decreased Fat Mass
Decreased Lean Mass

table cont’d.
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Measurements
Promethion Data
Fgf21

Results
Relative to AY

AY:Cpt1bm-/-

↓
↓
↓

Insulin
Triglycerides

AY:Cpt1bm-/- Relative to AY

Liver
Weight

↓
↓
↓
↓

Triglycerides
Glycogen
Fluid
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Discussion
4.1. Improvements in Metabolic Health
Inhibition of long chain fatty acid B-oxidation in the mitochondria of skeletal muscle has
rescued the metabolic health of genetically obese AY mice. Despite minimal changes in fat mass
and body weight, AY:Cpt1bm-/- mice drastically improve their performance during glucose
tolerance testing and insulin tolerance testing. In comparison to A Y mice, AY:Cpt1bm-/- mice have
significantly lower amounts of insulin and triglycerides in the circulation of 32-week-old mice in
the fasted state. Gene expression for enzymes involved with fatty acid synthesis were down in
the livers of AY:Cpt1bm-/- mice relative to AY mice and may explain the decrease in circulating
triglycerides. Additionally, hepatic triglycerides were numerically lower in A Y:Cpt1bm-/- mice
relative to AY mice and histology liver images appear to show a decrease in ectopic lipid
accumulation for AY:Cpt1bm-/- mice. Liver weights for AY:Cpt1bm-/- mice were significantly
lower than that of AY mice. Taken together, these data are suggestive of improved metabolic and
hepatic health in AY:Cpt1bm-/- mice even though there were minimal changes in fat mass and
body weight. The reason why Cpt1bm-/- mice exhibit a leaner phenotype is still under
investigation; however, Agouti mice must be blocked from having the effects of these anorectic
factors. The blocking may be due to the presence of the agouti protein. Further investigation is
needed in order to unmask the lingering questions of why Cpt1b m-/- mice become leaner when
long chain fatty acid B-oxidation is inhibited in skeletal muscle mitochondria and what is
preventing Agouti mice from doing the same.
4.2. Modifications Occurring in Skeletal Muscle of AY:Cpt1bm-/- Mice
Skeletal muscle-specific Cpt1b knock out in genetically obese AY mice appear to strongly
embody a model of lipid aggregation and FAO impairment. Expression of genes involved with
fatty acid binding (Fabp3), lipid droplet forming (Plin5) and fatty acid transport (Cd36, Fatp1)
were all significantly increased in gastrocnemius muscle of A Y:Cpt1bm-/- mice. Expression of
Hadha and Ech1, genes associated with mitochondrial FAO, were significantly upregulated in
AY:Cpt1bm-/- mice relative to Control mice. Furthermore, peroxisomal FAO appears to
compensate for impairment of mitochondrial FAO in muscle. Acyl-CoA oxidase 1 (Acox1), a
peroxisomal FAO gene, was found to be upregulated in AY:Cpt1bm-/- mice. Inhibition of fatty
acid oxidation appears to result in usage of alternative fuel sources in muscle. Bckdha and Bcat2,
genes associated with mitochondrial branched-chain amino acid cycle, were elevated in the
gastrocnemius of AY:Cpt1bm-/- mice.
As seen previously in muscle of Cpt1bm-/- mice, muscle of AY:Cpt1bm-/- mice appear to
undergo a plethora of effects that could be induced by an energy deficit signal elicited from
inhibition of B-oxidation. AMP-activated protein kinase (AMPK) is a sensor of cellular energy
status that becomes activated with a high ratio of AMP:ATP in the cell. AMPK is a promoter of
glucose uptake, fatty acid oxidation, mitochondrial biogenesis and insulin sensitivity (O'Neill,
2013). Previous work with Cpt1bm-/- mice found a significant increase in the phosphorylation of
the α-subunit of AMPK at Thr-172 relative to control mice. Additionally, AMPK target
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc1α) was found to be
robustly elevated in both red and white muscles (S. E. Wicks et al., 2015). Pgc1α is often
accredited as a master in the regulation of mitochondrial biogenesis and was elevated in
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AY:Cpt1bm-/- mice. This suggests that there may be more mitochondria in the skeletal muscle of
mice with the skeletal-muscle specific Cpt1b knock out. Increases in the number of mitochondria
in skeletal muscle may be partially responsible for improved glucose utilization. While Pgc1α
expression in gastrocnemius was found to be elevated in both Cpt1b m-/- and AY:Cpt1bm-/- mice,
phosphorylation of the α-subunit of AMPK at Thr-172 was never measured in A Y:Cpt1bm-/- mice.
Given that AY:Cpt1bm-/- mice have increased mitochondrial biogenesis in gastrocnemius,
improved glucose clearance and enhanced insulin sensitivity, we hypothesize the
phosphorylation of the α-subunit of AMPK at Thr-172 would follow a similar pattern in
AY:Cpt1bm-/- mice relative to Cpt1bm-/- mice. Additional work will be needed to confirm this
hypothesis.
4.3. The Impact of Fgf21
Expression of Fgf21 was elevated in the muscle of AY:Cpt1bm-/- mice. A double knockout
mouse model of Cpt1b and Fgf21 showed a partial negation in improved glucose utilization in
comparison to Cpt1b knock outs (Vandanmagsar et al., 2016). Fgf21 may be somewhat
responsible for the increase in glucose utilization when Cpt1b is knocked out in skeletal muscle.
However, there are definitely other factors contributing to these improvements and the relevance
of the physiological effects Fgf21 has on improved metabolic health in skeletal-muscle specific
Cpt1b knock out mice may be questionable. Transcriptomics and proteomic analyses could
potentially identify other contenders contributing to the improvements on metabolic health in
skeletal-muscle specific Cpt1b knock out mice.
Fgf21 in the serum of mice in the fed state was significantly elevated for A Y mice relative
to Control mice, but there was not statistical significance between A Y:Cpt1bm-/- mice and Control
mice. Elevated Fgf21 serum levels have been observed in genetically and diet-induced obese
mouse models. One study suggested that obesity is an Fgf21-resistant state. Their study
evaluated the response of obese mice to administration of exogenous Fgf21 and noted a
significantly reduced signaling response in diet-induced obese mice. They concluded by stating
diet-induced obesity results in elevated endogenous Fgf21 levels and poor response to
administration of exogenous Fgf21 (Fisher & Maratos-Flier, 2016). It is a possibility that the A Y
mice are experiencing an Fgf21 resistant state and AY:Cpt1bm-/- mice remain sensitive to Fgf21
via inhibition of skeletal muscle FAO, allowing for improved glucose utilization. However, this
suggestion needs further investigation.
4.4. Investigation of Decreased Liver Weight in A Y:Cpt1bm-/- Mice
Liver weights for AY:Cpt1bm-/- mice were significantly less than AY liver weights.
Triglyceride and glycogen content were numerically lower in A Y:Cpt1bm-/- mice and fluid levels
were significantly less than AY mice. The correlation plot between fluid and glycogen +
triglyceride content showed an R2 value of 0.5. Increased amounts of triglycerides and glycogen
content in the liver may be partially contributing to the increased fluid levels seen in the livers of
AY mice. Increased fluid retention in the liver may also be suggestive of hepatic inflammation.
Checking inflammatory biomarkers in the liver could potentially help with explaining the higher
fluid levels seen in the AY mice.
Also, gene expression of various enzymes involved in fatty acid synthesis was
upregulated in the livers of AY mice. Histology images show a larger amount of lipid
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accumulation in AY liver relative to AY:Cpt1bm-/- liver. Taken together, these data suggest
improvements in ectopic lipid accumulation in AY:Cpt1bm-/- liver relative to AY liver. These data
also indicate that the addition of the Cpt1b m-/- to the AY heterozygote genotype results in a
moderate, but important improvement in handling dietary energy.
4.5. Lower Respiratory Quotient in AY:Cpt1bm-/- Mice Relative to AY Mice
Pck1 was significantly elevated in the livers of AY:Cpt1bm-/- mice suggesting an
upregulation in hepatic gluconeogenesis. Coupled with numerically lower liver glycogen, the
increased amounts of liver Pck1 and decreased FAO indicate that the glucose product of
gluconeogenesis is being used for energy in the A Y:Cpt1bm-/- mice. Despite these findings, the
respiratory quotient for AY:Cpt1bm-/- mice was less than that of AY mice. This would suggest that
the AY:Cpt1bm-/- mice were actually utilizing more fat for fuel relative to A Y mice. Since the AY
mice are hyperglycemic, they may have a higher RQ because glucose is more readily available
for use. Additionally, enzymes involved with amino acid oxidation were upregulated in the
skeletal muscle of AY:Cpt1bm-/- mice, suggesting an increase in the reliance on protein as a fuel
source. Protein may be contributing to the decreased RQ seen in the A Y:Cpt1bm-/- mice; however,
it is likely to be minimal.
4.6. Possible Impact of Gdf15
Circulating triglycerides in serum of AY:Cpt1bm-/- mice fasted for 4 hours was found to be
significantly less relative to AY mice. While hepatic triglycerides content in AY:Cpt1bm-/- mice
were numerically lower than for AY mice, triglyceride content in circulation was significantly
lower in AY:Cpt1bm-/- mice. Livers of AY:Cpt1bm-/- mice appear to be holding on to hepatic
triglycerides rather than releasing into circulation, despite having numerically lower hepatic
triglycerides. Interestingly, hepatic expression of Gdf15 was found to be upregulated in AY liver
compared to the other groups of mice. Previous research has found that Gdf15 stimulated export
of hepatic triglycerides into plasma serum (Luan et al., 2019). An increase in lipid levels in any
specific tissue seems to correlate in the literature and in our models with an increase in the
amount of Gdf15 released from tissue (Lee et al., 2017; Li, Zhang, & Zhong, 2018). In our
model, AY mice have large amounts of ectopic lipid in the liver along with elevated expression of
hepatic Gdf15 and elevated triglycerides in circulation. While not conclusive, lipid overload
appears to lead to an induction of hepatic Gdf15 and could potentially be indicative of pathology.
Gdf15 has also been found to help stimulate weight loss and improve glucose tolerance
(Day et al., 2019). Gdf15 is known to behave similarly to Fgf21 in that both are stress induced
hormones. Notably, Gdf15 and Fgf21 were found to follow the same pattern in gastrocnemius of
all four mouse models included in this study. Given that Fgf21 has an established role in the
improvement of metabolic health in Cpt1b m-/- mice (Vandanmagsar et al., 2016), this raises the
question of whether or not similar results would be found in a double knock out mouse model of
Cpt1b and Gdf15. If Gdf15 was found to have a similar affect as Fgf21 on Cpt1bm-/- mice, this
would raise the question of why do different physiological conditions lead to the release of these
hormones from different sources and what does the source suggest? Hepatic release of Gdf15
could possibly be suggestive of pathology while skeletal muscle release might indicate a
favorable adaptation.
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4.7. Limitations and Suggestions for Future Work
A large limitation to this pilot study is a low number of mice. Further investigation is
needed with a larger number of mice per group. In future studies, the measurement of the
phosphorylation of the α-subunit of AMPK at Thr-172 in A Y:Cpt1bm-/- mice relative to Control
and AY mice would further elaborate the metabolic effects of the skeletal muscle homozygote
knock out of Cpt1b. Chemical analysis of triglycerides in the liver, serum and histology images
of ectopic fat in the liver were the only lipid measure that we assessed. There are other lipids that
we have not quantified but the triglyceride content provides evidence that fats were decreased in
serum and liver. It would be worthwhile to have the hepatic histology images scanned in order to
quantify the amount of lipid droplets shown in these images. We recommend that future studies
should also quantify other fats in the liver and serum. Creation of a double knockout mouse
model of skeletal muscle specific Cpt1bm-/- and Gdf15 is recommended to determine if Gdf15
plays a favorable role in the improved glucose utilization in Cpt1b m-/- mice. In addition to this,
creation of a liver specific Gdf15 knockout in AY mice is also recommended to determine if
hepatic Gdf15 influences plasma triglyceride levels. Further investigation is needed to determine
additional factors contributing to the improved metabolic health when Cpt1b is knocked out in
skeletal muscle. Transcriptomics and proteomic analyses of A Y and AY:Cpt1bm-/- mice would be
worthwhile in order to determine potential transcriptomes and proteomes contributing to the
ameliorated glucose utilization and insulin sensitivity.
Previous transcriptomic analysis of Cpt1b m-/- mice showed that Gdf15 was upregulated
relative to control mice. Cpt1bm-/- mice had significantly less fat mass and body weight relative
to control mice. The reasons for this leaner phenotype are not fully understood; however,
increases in Gdf15 may contribute to the decreases in fat mass and body weight. Gene expression
showed that AY:Cpt1bm-/- mice also have increased expression of Gdf15 in skeletal muscle
relative to AY mice. Given that Gdf15 is an anorectic hormone, one might expect this increase in
expression to lead to weight loss in AY:Cpt1bm-/- mice relative to AY mice. However, differences
in weight and fat mass were minimal and not significantly different between groups. This lack of
weight loss might suggest that the ubiquitous expression of agouti is interfering with the
signaling of Gdf15 with receptors in the brain. Gdf15 is known to bind to the Gfral receptor in
the brain. We think Gdf15 may also signal additional receptors in the brain.
We know the ubiquitous overexpression of agouti blocks the Mcr4, preventing alphamelanocyte stimulating hormone from binding and driving yellow obese syndrome in A Y mice.
We suspected that this blockage of Mcr4 by agouti could also be interfering with the signaling of
Gdf15, thus preventing the anorectic implications of this hormone. However, Gdf15 has been
found to reverse hyperphagia and obesity in a melanocortin 4 receptor deficient rat model (Hsu
et al., 2017). Therefore, Gdf15 does not appear to signal the Mcr4 receptor. It is still possible that
Gdf15 could signal other receptors in the brain besides Gfral and additional research is needed to
determine this. If Gdf15 is found to be responsible for the leaner phenotype in the Cpt1b m-/- mice,
then the lack of weight loss seen in the AY:Cpt1bm-/- mice may suggest that the overexpression of
agouti is also somehow interfering with the signaling of Gdf15 in the AY:Cpt1bm-/- mice. Gdf15
will need to be knocked out in Cpt1bm-/- mice to determine if it is responsible for any of the
improvements in metabolic health seen in the Cpt1bm-/- mice. Additionally, if knocking out
Gdf15 in Cpt1bm-/- mice results in diminished weight loss, then the next step would be to knock
out Gfral in Cpt1bm-/- mice in order to determine if other receptors are involved in the signaling
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of Gdf15. If knocking out Mcr4 in the brain of Cpt1bm-/- mice still resulted in a leaner phenotype,
then this would be one way to further confirm that Gdf15 does not signal the Mcr4 receptor. The
further investigation of the leaner phenotype found in Cpt1b m-/- mice could potentially help with
furthering the understanding of Gdf15 signaling in the brain.
4.8. Applications to the Treatment of Obesity and Diabetes
Inhibition of long chain fatty acid B-oxidation has proven to be effective for improving
insulin sensitivity and glucose utilization in two mouse models, including one model of genetic
obesity. In fact, inhibition of skeletal muscle long chain fatty acid B-oxidation resulted in a
leaner phenotype in regular C57BL/6 mice. Genetically obese A Y mice managed to maintain
their obesity despite inhibition of long chain fatty acid B-oxidation in skeletal muscle. Further
investigation is needed to fully understand what causes and protects against a leaner phenotype
in each of these models, respectively. As of now, inhibition of Cpt1b in skeletal muscle appears
to offer a therapeutic target for the treatment of insulin resistance. Currently, the three known
inhibitors of Cpt1 are Etomoxir, Oxfenicine and Perhexiline CPT-I. Unfortunately, it is hard for
these inhibitors to specifically target skeletal muscle without negatively impacting the heart and
liver as well. The potential for Cpt1b to serve as a pharmacological therapy for skeletal muscle
insulin resistance is limited until the specificity of these inhibitors is established. Additional
research will be needed in order to make this into an efficacious treatment plan.
4.9. Concluding Thoughts
In aggregate, our results showed Cpt1b inhibition in skeletal muscle to be efficacious
from a treatment standpoint for improving insulin resistance even in the Agouti mouse model
with severe obesity and diabetes, despite no significant change in adiposity. Overall, inhibition of
long chain fatty acid B-oxidation in skeletal muscle of A Y mice has proven to embody a mouse
model in a metabolically healthy, yet obese state. Further investigation is needed in order to
unveil the mechanisms driving the improvements in metabolic health that are observed when
Cpt1b is inhibited in skeletal muscle.
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